Literature DB >> 6578003

Antihypertensive effect of indapamide with special emphasis on renal prostaglandin production.

M LeBel, J H Grose, L J Belleau, S Langlois.   

Abstract

A study was undertaken in 19 patients with benign to moderate essential hypertension to verify the effect of indapamide alone or combined with a beta-blocker on plasma renin activity, plasma aldosterone, serum potassium and urinary prostaglandins PGE2 and PGF2a. Blood pressure was normalized in 11 (58%) patients with 2.5 mg indapamide/day. In the remaining 8 patients, the addition of pindolol resulted in blood pressure control. Under indapamide, a 70% increase in plasma renin activity and 81% (p less than 0.01) in plasma aldosterone was observed, whereas there was an 18% (p less than 0.001) decrease in potassium. Simultaneously, an increase in urinary PGE2 and PGF2a was observed; these values were significant for PGE2 (p less than 0.025). The addition of pindolol did not produce significant change in the biochemical parameters measured. The increase in the excretion rate of primary prostaglandins could play a role in the mode of action of indapamide.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6578003     DOI: 10.1185/03007998309109841

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

1.  Effect of indapamide on the renin-aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.

Authors:  H Danielsen; E B Pedersen; E S Spencer
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

2.  Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension.

Authors:  M Chaffman; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

3.  Redefining diuretics use in hypertension: why select a thiazide-like diuretic?

Authors:  Michel Burnier; George Bakris; Bryan Williams
Journal:  J Hypertens       Date:  2019-08       Impact factor: 4.844

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.